Gabapentin and motor fluctuations in parkinson's disease
✍ Scribed by Pedro Chaná; Alejandro de Marinis; Nelson Barrientos
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 110 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
We read with interest the abstract by Olson et al. (I). They showed that gabapentin improves rigidity, bradykinesia, and tremor in parkinsonism and Parkinson's disease (PD).
We administered gabapentin, 900 mg per day, in an open trial to seven nondemented patients with PD who had painful dystonia, dyskinesia, and motor fluctuations (Table 1) Gabapentin effect was measured with the Unified PD Rating Scale (UPDRS) and Obeso Dyskinesia Rating scale (2).
Gabapentin improved interdose symptoms (painful dystonia, biphasic dyskinesias) and motor fluctuations (on time). Palpitations, perspiration, and mood changes also seemed to improve, although this was not quantitatively evaluated. We also observed the beneficial effects on parkinsonian symptoms proposed by Olson et al. (Table 2).
The mechanism by which gabapentin exerts its antiparkinsonian effects is unknown. It does not exhibit affinity to dopamine D, or D,, or glutamatergic or cholinergic receptors (3,4).
Gabapentin was tolerated well. Only two patients developed somnolence, which could be managed with dose reductions.
📜 SIMILAR VOLUMES
There are some confusing details in the recent Annals article by the Parkinson Study Group (PSG), concerning the use of entacapone.'
In questioning the diagnosis of a What is it? case (l), Quinn and Hardie (2) state that in their experience linear streaks of increased signal in the putamen on magnetic resonance imaging (MRI) are not seen in Huntington's disease but were seen in four of their cases of neuroacanthocytosis (3). In t
Loss of dopamine neurons in Parkinson's disease (PD) initiates a complex stream of effects that results in the development of tremor, bradykinesia, and rigidity. While levodopa remains the most effective drug for the symptomatic treatment of PD, its chronic administration is associated with the deve
Fluctuations in the symptoms of Parkinson's disease (PD), such as wearing-off and on-off effects, and dyskinesias are related to a variety of factors, including duration and dosage of levodopa, age at onset, stress, sleep, food intake, and other pharmacokinetic and pharmacodynamic mechanisms. The ma